Meloxicam - Iroko Pharmaceuticals

Drug Profile

Meloxicam - Iroko Pharmaceuticals

Alternative Names: IP 045; VIVLODEX

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator iCeutica
  • Developer iCeutica; Iroko Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Amides; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines; Thiazoles
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Musculoskeletal pain

Most Recent Events

  • 06 Jan 2017 Iroko Pharmaceuticals has patent protection for meloxicam in USA
  • 30 Jun 2016 Discontinued - Phase-I for Musculoskeletal pain in Australia (PO) prior to June 2016
  • 12 May 2016 The US approved label for meloxicam carries a black box warning related to an increased risk of serious cardiovascular and gastrointestinal adverse events
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top